HIV/AIDS News

  • Home
  • HIV/AIDS News
  • Corrections to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Corrections to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Date: April 27, 2015
Source: AIDSinfo

On April 27, 2015, the following updates were made to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection  (released March 5, 2015):

  • In When to Initiate Therapy, the urgent treatment recommendations were updated to include CDC Stage 3-defining opportunistic infections in children aged ≥1 year. The update reads:

  • "Age ≥1 Year:
    • CDC Stage 3-defining opportunistic illnesses (AI*)”
  • In Table 8 in What Drugs to Start, regimens for “children aged ≥12 years” was updated to “children aged ≥12 years and weighing ≥40 kg.”
  • In the What Drugs Not to Start section, Table 10 was updated to include dolutegravir-based regimens for children aged <12 years or weighing <40 kg.
  • In the Tenofovir, Emtricitabine, and Rilpivirine sections, dosing information for Complera was revised to include virologically suppressed adults. Additionally, wording was adjusted to detail that Complera should be administered with a meal and Atripla should be administered without food. Additionally:
    • Wording in Emtricitabine  was added to include that “Stribild should not be initiated in patients with estimated CrCl <70 mL/min and should be discontinued in patients with estimated CrCl <50 mL/min.”
    • Wording in Rilpivirine  was added to include that “Complera (fixed-dose combinations) should not be used in patients with CrCl <50 mL/min or in patients requiring dialysis.”